Vitiligo
From Anvita Health Wiki
Contents |
Etiology
- presumed autoimmune in origin, anti- melanocyte
- often seen in association with autoimmune disorders
- thyroid disease
- acquired condition, congenital cases are rare
Epidemiology
- incidence is approximately 1%
- affects both sexes equally
- more noticeable in dark-skinned individuals
- peak incidence between 10-30 years
Pathology
- absence of melanocytes
- minimal inflammation
Genetics
- 30% of patients have an affected family member
- inheritance pattern is unclear
- mutations in gene for F-box only protein-11
Clinical-manifestations
-
- 1 mm to several cm in diameter
- generally white, but may be off-white or tan in color
- circular or oval in shape, may have scalloped edges
- accentuated by viewing with Wood's lamp, especially in light-skinned patients
- focal, segmental or generalized in distribution
- generalized vitiligo tends to occur in a symmetric pattern
- common sites include
- other skin manifestations
- iritis is seen in 10% of patients with vitiligo
- signs associated with concomitant autoimmune disorder
Laboratory
- diagnosis is made by history & physical examination, laboratory testing is rarely needed
- skin biopsy reveals normal skin except for an absence of melanocytes
- screening tests for associated autoimmune disorders
- free T4 or TSI & serum TSH
- complete blood count ( CBC) for pernicious anemia
- fasting blood sugar ( serum glucose) for diabetes mellitus
- serum Na+, serum K+ & serum cortisol for Addison's disease
Diagnostic-procedures
- lesions more apparent under Wood's lamp ( chalk white)
Differential-diagnosis
Management
- primarily of cosmetic & social concern
- tends to be stable initially, then progresses over several years
- untreated vitiligo usually remains for life, but some individuals spontaneously repigment depigmented areas
- sunscreens ( SPF > 30) will diminish pigmentation of adjacent areas which make the vitiligo more noticeable
- cosmetics may provide good results
- pharmacologic agents
- topical steroids for isolated lesions
- hydrocortisone 1% or 2.5% on face & skin folds
- more potent steroids elsewhere
- use interrupted schedule if steroids are used for more than 6-8 weeks to reduce risk of steroid atrophy
- depigmentation of normal skin with monobenzone (Benzoquin)
- permanent, uniform bleaching of remaining normal skin
- may be useful for patients with extensive disease
More General Terms
Additional Terms
Internet Database
OMIM: 193200
References
- Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 952-53
- Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 296
- Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009
- NIH Institute and Center Resources [1]
- National Guideline Clearinghouse Guideline for the diagnosis and management of vitiligo. British Association of Dermatologists ngc-guideline: [2]
